-opioid receptor antagonist (Ki
values are 5.4, 244.6 and 2187 nM for μ
- and κ
-opioid receptors respectively). Reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Synthesis and biological evaluation of 14-alkoxymorphinans. 11. 3-hydroxycyprodime and analogues: opioid antagonist profile in comparison to cyprodime.
Schmidhammer et al.
μ-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPγs binding assays.
Marki et al.
μ- and δ-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Henry et al.
The citations listed below are publications that use Tocris products. Selected citations for Cyprodime hydrochloride include:
Showing Results 1 - 1 of 1